WallStreetZenWallStreetZen

NASDAQ: GALT
Galectin Therapeutics Inc Stock Ownership - Who owns Galectin Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Galectin Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Richard E. UihleinDirector2026-01-1613,158$3.04
$40.00kBuy
Khurram JamilChief Medical Officer2026-01-0621,446$3.65
$78.21kSell
Jack W. CallicuttChief Financial Officer2026-01-0620,354$3.67
$74.70kSell
Joel LewisPresident and CEO2026-01-0637,698$3.58
$134.85kSell
Joel LewisPresident and CEO2026-01-0556,332$3.88
$218.57kSell
Jack W. CallicuttChief Financial Officer2026-01-0525,732$3.90
$100.30kSell
Khurram JamilChief Medical Officer2026-01-0525,499$3.90
$99.40kSell
Joel LewisPresident and CEO2026-01-0527,731$3.91
$108.35kSell
Jack W. CallicuttChief Financial Officer2026-01-0213,914$4.20
$58.40kSell
Joel LewisPresident and CEO2026-01-0218,571$4.20
$77.94kSell

1 of 13

GALT insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GALT insiders and whales buy or sell their stock.

GALT Shareholders

What type of owners hold Galectin Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
10x Fund LP34.54%22,271,880$65.92MInsider
James C. Czirr32.60%21,015,907$62.21MInsider
Rod D. Martin18.70%12,057,197$35.69MInsider
Richard E. Uihlein16.07%10,360,386$30.67MInsider
David Platt13.06%8,418,743$24.92MInsider
Vanguard Group Inc3.49%2,247,967$6.65MInstitution
Osaic Holdings Inc1.90%1,224,724$3.63MInstitution
Joel Lewis1.30%836,592$2.48MInsider
Blackrock Inc1.24%797,669$2.36MInstitution
Geode Capital Management LLC0.98%633,067$1.87MInstitution

1 of 3

GALT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GALT11.90%88.10%Net SellingNet Selling
SRZN23.62%76.38%Net BuyingNet Buying
SLGL20.05%16.55%Net BuyingNet Buying
NTHI8.71%91.29%Net BuyingNet Buying
IRD5.79%94.21%Net SellingNet Selling
View Top Biotech Stocks

Galectin Therapeutics Stock Ownership FAQ

Who owns Galectin Therapeutics?

Galectin Therapeutics (NASDAQ: GALT) is owned by 15.92% institutional shareholders, 117.87% Galectin Therapeutics insiders, and 0.00% retail investors. 10x Fund LP is the largest individual Galectin Therapeutics shareholder, owning 22.27M shares representing 34.54% of the company. 10x Fund LP's Galectin Therapeutics shares are currently valued at $63.03M.

If you're new to stock investing, here's how to buy Galectin Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.